Project 1

Combination Anticancer Nanopreparations of Novel Proapoptotic Drug and siRNA

Project Leader: Vladimir P. Torchilin, PhD
Co-Investigator: Alexei Degterev, PhD

The current project is an integral part of our CCNE proposal which aims to develop, characterize in vitro, test in animal models, and scale up in an industrial setting a broad set of novel multifunctional nanocarriers for targeted delivery of various drugs including DNA, siRNA, and diagnostic agents to solid tumors in vivo for the purposes of cancer therapy and diagnostics, especially for multidrug resistant (MDR) tumors. Within the general program, this proposal will cover a combination nanopreparations containing a novel, powerful proapoptotic agent, siRNA [to downregulate cancer cell defense mechanisms (such as Pgp)], and Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL), a cytokine of the TNFα family, a novel promising, selective anti-cancer agent. This combination micellar preparation will be additionally modified with a tumor-specific targeting antibody (for systemic administration) or with the cell-penetrating TAT peptide (TATp) for intratumoral administration).

Our proposal is based on several interrelated challenges. First, effective therapy of a cancer, especially in the case of MDR tumors still represents an important medical need. Second, many newly discovered or synthesized proapoptotic anticancer agents, which could serve as an effective means to treat cancer in combination with TRIAL by upregulating apopototic mechanisms in cancer cells, cannot now serve as practical drugs because of their poor solubility and low stability in vivo. Third, siRNAs (that downregulate tumor defense mechanisms) have very low stability in the body and multiple delivery problems. We propose to overcome these challenges by formulating a combination of new agents into self-assembling pharmaceutical nanocarriers (lipid-core micelles) specifically targeted to and into cancer cells. Such formulations will allow for an efficient solubilization of a poorly soluble proapoptotic drug, stabilization of the drug or a siRNA in the body, and their efficient co-delivery together with TRIAL into targeted tumors.

Thus, within the overarching organizing framework, this project will provide multifunctional micellar combinations of nanopreparations to specifically deliver a proapoptotic drug, a siRNA, and TRIAL to various tumors, particularly, to MDR tumors.

  • Contact:

    Marina Sheynina
    Phone: 617-373-6004
    Fax: 617-373-7509
    m.sheynina@neu.edu